2 weeks Ago By Defense World Staff
Geode Capital Management LLC boosted its stake in Sage Therapeutics, Inc. ( NASDAQ:SAGE – Free Report ) by 1.1% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission.
The fund owned 1,256,903 shares of the biopharmaceutical company’s stock after buying an additional 14,049 shares during the quarter. Geode Capital Management LLC owned approximately 2.05% of Sage Therapeutics worth $6,827,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. raised its position in Sage Therapeutics by 157.
9% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 169,057 shares of the biopharmaceutical company’s stock worth $918,000 after acquiring an additional 103,495 shares during the period.
Thrivent Financial for Lutherans increased its stake in shares of Sage Therapeutics by 108.7% during the 4th quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company’s stock worth $405,000 after purchasing an additional 38,876 shares during the last quarter.
Fox Run Management L.L.C.
raised its holdings in shares of Sage Therapeutics by 199.0% in the 4th quarter. Fox Run Management L.
L.C. now owns 48,950 shares of the biopharmaceutical company’s stock worth $266,000 after purchasing an additional 32,579 shares during the period.
Amundi purchased a new position in Sage Therapeutics in the fourth quarter valued at approximately $166,000. Finally, Inspire Investing LLC grew its holdings in Sage Therapeutics by 30.4% during the fourth quarter.
Inspire Investing LLC now owns 75,313 shares of the biopharmaceutical company’s stock valued at $409,000 after purchasing an additional 17,541 shares during the period. 99.22% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets Several brokerages have issued reports on SAGE. Bank of America began coverage on Sage Therapeutics in a research note on Tuesday, March 11th. They issued an “underperform” rating and a $5.
00 target price on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Canaccord Genuity Group reduced their target price on shares of Sage Therapeutics from $9.
00 to $8.00 and set a “hold” rating for the company in a research note on Wednesday, February 12th. Piper Sandler dropped their price target on shares of Sage Therapeutics from $26.
00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday, January 2nd. Finally, Wedbush reiterated a “neutral” rating and issued a $6.
00 price objective on shares of Sage Therapeutics in a research note on Wednesday, February 12th. Three investment analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.
com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8.81. Sage Therapeutics Price Performance SAGE stock opened at $7.
79 on Friday. The firm has a 50 day simple moving average of $7.51 and a two-hundred day simple moving average of $6.
74. The stock has a market cap of $478.94 million, a PE ratio of -1.
18 and a beta of 0.48. Sage Therapeutics, Inc.
has a one year low of $4.62 and a one year high of $14.97.
Sage Therapeutics ( NASDAQ:SAGE – Get Free Report ) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) EPS for the quarter, missing analysts’ consensus estimates of ($1.
54) by ($0.02). Sage Therapeutics had a negative net margin of 971.
50% and a negative return on equity of 68.18%. On average, research analysts expect that Sage Therapeutics, Inc.
will post -3.52 EPS for the current fiscal year. Sage Therapeutics Company Profile ( Free Report ) Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines.
Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Recommended Stories Five stocks we like better than Sage Therapeutics Why Are These Companies Considered Blue Chips? 2 Strong Utilities Plays With Booming Earnings and Room to Grow What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story Why Smart Investors Don’t Panic in Election Season EV Stocks and How to Profit from Them Now Is the Time to Buy ServiceNow—The Rebound Is Real Receive News & Ratings for Sage Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter .
.
